SCHEMBL6705137

SCHEMBL6705137

CN(C(=O)OCc1ccccc1)[C@@H](CC(=O)O)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.53
ITGB3 P05106 1/20 0.47
ITGA2B P08514 1/20 0.47
ALDH1A1 P00352 4/20 0.47
FOLH1 Q04609 2/20 0.47
CTSL P07711 1/20 0.45
CTSB P07858 1/20 0.45
CTSS P25774 1/20 0.45
CTSK P43235 1/20 0.45
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CPA1 P15085 2/20 0.41
SIGMAR1 Q99720 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27519798 1.00 ABCB1 (0.53) ABCB1ITGB3ITGA2BALDH1A1FOLH1
SCHEMBL23879154 0.90 ABCB1 (0.52) ABCB1ITGB3ITGA2BALDH1A1FOLH1
SCHEMBL6370564 0.89 ABCB1 (0.51) ABCB1ITGB3ITGA2BALDH1A1FOLH1
SCHEMBL29860914 0.87 ABCB1 (0.46) ABCB1ITGB3ITGA2BALDH1A1FOLH1
SCHEMBL6370553 0.87 ABCB1 (0.51) ABCB1ITGB3ITGA2BALDH1A1FOLH1
SCHEMBL2494968 0.87 ITGB3 (0.59) ABCB1ITGB3ITGA2BALDH1A1FOLH1
SCHEMBL31739224 0.87 ITGB3 (0.59) ABCB1ITGB3ITGA2BALDH1A1FOLH1
SCHEMBL8067076 0.87 ITGB3 (0.59) ABCB1ITGB3ITGA2BALDH1A1FOLH1
SCHEMBL2968658 0.87 ITGB3 (0.59) ABCB1ITGB3ITGA2BALDH1A1FOLH1
SCHEMBL21874257 0.87 ABCB1 (0.51) ABCB1ITGB3ITGA2BALDH1A1FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114920669-A Synthesis method of N-methyl-N-benzyloxycarbonyl-L-aspartic acid (4-tert-butyl ester) dicyclohexylamine salt 吉尔多肽生物制药(大连市)有限公司 2022-08-19 CN claimed
CN-118475590-A N-alkylamino acid and method for producing peptide containing N-alkylamino acid 中外制药株式会社 2024-08-09 CN disclosed
CN-113454058-B Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same 中外制药株式会社 2024-03-22 CN disclosed
CN-117279933-A Cyclic compounds having selective KRAS inhibition relative to HRAS and NRAS 中外制药株式会社 2023-12-22 CN disclosed
CN-114920669-A Synthesis method of N-methyl-N-benzyloxycarbonyl-L-aspartic acid (4-tert-butyl ester) dicyclohexylamine salt 吉尔多肽生物制药(大连市)有限公司 2022-08-19 CN disclosed
CN-114920669-A Synthesis method of N-methyl-N-benzyloxycarbonyl-L-aspartic acid (4-tert-butyl ester) dicyclohexylamine salt 吉尔多肽生物制药(大连市)有限公司 2022-08-19 CN disclosed
CN-114920669-A Synthesis method of N-methyl-N-benzyloxycarbonyl-L-aspartic acid (4-tert-butyl ester) dicyclohexylamine salt 吉尔多肽生物制药(大连市)有限公司 2022-08-19 CN disclosed
CN-114867734-A Method for synthesizing peptide compound 中外制药株式会社 2022-08-05 CN disclosed
US-20040220148-A1 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-11-04 US disclosed
CN-1187490-A 5-membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists HOECHST AG (DE) 1998-07-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220148-A1 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists VCAM1, LTB4R, ITGB4 ABCB1 433/4885ITGB3 23/4885ITGA2B 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.